These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9932078)

  • 1. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging DNA topisomerase inhibitors as anticancer drugs.
    Denny WA
    Expert Opin Emerg Drugs; 2004 May; 9(1):105-33. PubMed ID: 15155139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
    Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
    Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 5. [NB 506].
    Lansiaux A; Bailly C
    Bull Cancer; 1999 Mar; 86(3):255-8. PubMed ID: 10210758
    [No Abstract]   [Full Text] [Related]  

  • 6. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to topoisomerase I-targeting drugs.
    Rasheed ZA; Rubin EH
    Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
    Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerases in cancer therapy.
    Lock RB; Ross WE
    Anticancer Drug Des; 1987 Oct; 2(2):151-64. PubMed ID: 2835059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
    Lin JH; Castora FJ
    Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy.
    Smith PJ
    Bioessays; 1990 Apr; 12(4):167-72. PubMed ID: 2159289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
    Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
    Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.
    Sané AT; Bertrand R
    Cancer Res; 1999 Aug; 59(15):3565-9. PubMed ID: 10446962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [DNA topoisomerases and resistance to anticancer agents].
    Andoh T; Okada K
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):569-75. PubMed ID: 2539786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel camptothecin derivatives as topoisomerase I inhibitors.
    Basili S; Moro S
    Expert Opin Ther Pat; 2009 May; 19(5):555-74. PubMed ID: 19441934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.